Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1371

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 6
Chunk 1371
---
 a member of governmental committees. He
received his Ph.D. from University of Houston and worked as a post-doc in Baylor College of Medicine. Dr. Cho is an author of
more than 80 publications in books and journals including Nature, and an inventor of more than 200 patents filed. Dr. Cho is well
qualified to serve as a Director because of long-standing career experiences both as a biotech entrepreneur and the R&D Head
of a major life sciences company in Korea (LG Group).

Number and Terms of Office of Officers and Directors 

We have seven directors and five officers. In accordance with Nasdaq
corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following
our listing on Nasdaq. The term of office of our initial directors will expire at our first annual meeting of stockholders.

Our officers are appointed by the board of directors and serve at the
discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons
to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our officers may consist of a Chairman of the
Board, a Chief Executive Officer, Chief Financial Officer, President, Vice Presidents, Secretary, Treasurer, Assistant Secretaries and
such other offices as may be determined by the board of directors.

Changes in Company Directors during the reporting period

On May 24, 2024, Steven Reed provided notice of his resignation
as a member of the Company’s Board of Directors (the “Company Board”) effective immediately, including his chairmanship
of the Company Board, his chairmanship and service on the Compensation Committee of the Company Board, and his service on the M&A
Committee. Dr. Reed’s resignation was not the result of any dispute or disagreement with the Company or the Company Board on
any matter relating to the Company’s operations, policies or practices.

On May 27, 2024, the Company Board appointed Mr. Phil Geon Lee
as a director, effective immediately. Mr. Lee was appointed as a member of the Audit Committee of the Company Board, filling the
vacancy created by the resignation of Hosun Euh, as previously reported by the Company on Form 8-K filed with the SEC on June 14,
2023. The Company Board also appointed Jin Whan Park to act as chairman of its Audit Committee. Additionally,